Literature DB >> 8494042

Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model.

K Nakamura1, N Murase, M J Becich, T Furuya, S Todo, J J Fung, T E Starzl, A J Demetris.   

Abstract

A sequential analysis of liver allograft rejection in sensitized rats using immunopathological and ultrastructural microscopy is described. Lewis rats were primed with four ACI skin grafts and challenged with an arterialized ACI orthotopic liver allograft 14 to 17 weeks later. The sensitization resulted in a mix of IgG and IgM lymphocytotoxic antibodies at a titer of 1:512 at the time of transplantation. Specificity analysis of pretransplant immune sera revealed a predominance of IgG anti-class I major histocompatibility complex (RT1) antibodies with a minor IgG fraction showing apparent endothelial cell specificity (non-RT1). This level of sensitization was associated with accelerated graft failure in 3 to 5 days from mixed humoral and cellular rejection. Sequential analysis of serial posttransplant graft biopsies revealed diffuse vascular IgG deposition and platelet thrombi in portal veins and periportal sinusoids within 3 minutes after reperfusion. This was followed by endothelial cell hypertrophy and vacuolization, periportal hepatocyte necrosis, arterial spasm, focal large bile duct necrosis, and hilar mast cell infiltration and degranulation. However, the liver allografts did not fail precipitously and hyperacute rejection was not seen. Kupffer cell phagocytosis of the sinusoidal platelets began as early as 30 minutes posttransplant and by 24 hours, the platelet thrombi had decreased. Cholangioles appeared focally at the edge of the limiting plates by 2 to 3 days, apparently in response to earlier periportal hepatocyte damage. A mononuclear portal and perivenular infiltrate became evident at 3 days, and graft failure was attributed to both antibody and cell-mediated rejection (Furuya et al: Preformed lymphocytotoxic antibodies: Hepatology 1992, 16: 1415-1422). The model described resembles observations in crossmatch positive human liver allograft recipients. The mechanisms of hepatic graft resistance to antibody mediated rejection and the possible long term consequences of early damage to the biliary tree are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494042      PMCID: PMC1886908     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage.

Authors:  T R Billiar; R D Curran; B G Harbrecht; D J Stuehr; A J Demetris; R L Simmons
Journal:  J Leukoc Biol       Date:  1990-12       Impact factor: 4.962

2.  Hyperacute rejection in liver transplantation: a case report.

Authors:  G Bird; P Friend; P Donaldson; J O'Grady; B Portmann; R Calne; R Williams
Journal:  Transplant Proc       Date:  1989-08       Impact factor: 1.066

3.  Intraoperative blood transfusions in highly alloimmunized patients undergoing orthotopic liver transplantation.

Authors:  T Weber; I R Marino; Y G Kang; C D Esquivel; T E Starzl; R J Duquesnoy
Journal:  Transplantation       Date:  1989-05       Impact factor: 4.939

Review 4.  New insights into "the riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity.

Authors:  S J Galli
Journal:  Lab Invest       Date:  1990-01       Impact factor: 5.662

5.  Signs of hyperacute rejection of liver grafts in rhesus monkeys after donor-specific presensitization.

Authors:  G Gubernatis; W Lauchart; M Jonker; G Steinhoff; A Bornscheuer; P Neuhaus; A A van Es; J Kemnitz; K Wonigeit; R Pichlmayr
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

6.  Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response.

Authors:  L Makowka; C Miller; P Chapchap; L Podesta; C Pan; D Pressley; V Mazzaferro; C O Esquivel; S Todo; B Banner
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

7.  Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers.

Authors:  A J Demetris; R Jaffe; A Tzakis; G Ramsey; S Todo; S Belle; C Esquivel; R Shapiro; B Markus; E Mroczek
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

8.  Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury.

Authors:  S Kakizoe; K Yanaga; T E Starzl; A J Demetris
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

9.  Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts.

Authors:  K P Batts; S B Moore; J D Perkins; R H Wiesner; P M Grambsch; R A Krom
Journal:  Transplantation       Date:  1988-02       Impact factor: 4.939

10.  Soluble HLA antigens in the circulation of liver graft recipients.

Authors:  H S Davies; S G Pollard; R Y Calne
Journal:  Transplantation       Date:  1989-03       Impact factor: 4.939

View more
  9 in total

1.  Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts.

Authors:  N Murase; S Fujisaki; M Tanabe; A C Tsamandas; S Todo; T E Starzl; A J Demetris
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

Review 2.  Chronic Rejection After Intestinal Transplant: Where Are We in Order to Avert It?

Authors:  Augusto Lauro; Mihai Oltean; Ignazio R Marino
Journal:  Dig Dis Sci       Date:  2018-01-11       Impact factor: 3.199

Review 3.  The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?

Authors:  A J Demetris; N Murase; C P Delaney; M Woan; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

4.  Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss.

Authors:  Jacqueline G O'Leary; Hugo Kaneku; Anthony J Demetris; John D Marr; S Michelle Shiller; Brian M Susskind; Glenn W Tillery; Paul I Terasaki; Göran B Klintmalm
Journal:  Liver Transpl       Date:  2014-01-02       Impact factor: 5.799

5.  Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.

Authors:  Jacqueline G O'Leary; S Michelle Shiller; Christopher Bellamy; Michael A Nalesnik; Hugo Kaneku; Linda W Jennings; Kumiko Isse; Paul I Terasaki; Göran B Klintmalm; Anthony J Demetris
Journal:  Liver Transpl       Date:  2014-10       Impact factor: 5.799

Review 6.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

7.  Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance.

Authors:  R Mañez; R H Kelly; M Kobayashi; S Takaya; O Bronsther; D Kramer; R J Duquesnoy; Y Iwaki; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

Review 8.  The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives.

Authors:  Elaine Y Cheng
Journal:  J Immunol Res       Date:  2017-01-09       Impact factor: 4.818

9.  The impact of preformed donor-specific antibodies in living donor liver transplantation according to graft volume.

Authors:  Ryoichi Goto; Makoto Ito; Norio Kawamura; Masaaki Watanabe; Yoshikazu Ganchiku; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi
Journal:  Immun Inflamm Dis       Date:  2022-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.